Key result
Exogenous IGF-II delivered to the infarct area improves regional cardiac performance at four weeks post-infarction.
Why the study?
Does exogenous IGF-II improve regional myocardial function post-infarction in a swine model?
Does exogenous IGF-II improve regional myocardial function post-infarction in a swine model?
Absolute Event Rate: 1.17% vs 3.42%
p-value: p=0.04
Exogenous IGF-II delivered to the infarct area improves regional cardiac function and induces peri-infarct myocyte growth in a swine model of myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Does not support clinical IGF-II use post-MI; hypothesis-generating for myocyte regeneration in large-animal models.
Battler et al. (1995) studied Myocardial infarction (n=12). Exogenous insulin-like growth factor II (IGF-II) vs. Control was evaluated on Echocardiographic segmental wall motion score at 4 weeks post-infarction (p=0.04). Exogenous IGF-II delivered to the infarct area significantly improved regional cardiac performance at 4 weeks post-infarction compared to controls (P=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: